The diabetes-associated allele at rs7903146 in the TCF7L2 locus predisposes to type 2 diabetes (T2DM). Recent work has shown that this variant is associated with impaired postprandial glucagon suppression. Since defects in α-cell function occur independently of impaired β-cell function, we hypothesized that impaired glucagon suppression could accelerate progression to T2DM. Therefore, we recruited 73 nondiabetic subjects with prior (6.7 ± 0.3 years) measurement of β-cell function using the oral minimal model (Baseline) and compared these indices to those obtained during a repeat Experiment (Present). Weight increased slightly, but significantly (2.8 ± 0.7 Kg, p < 0.01) over the period of study. Overall Disposition Index (DI) which expresses β-cell responsivity (ϕ) as a function of insulin action (Si) did not change (1234±160 vs. 1143±116 10-14, dl/kg/min2 per pmol/l, DIBaseline vs. DIPresent, p=0.55). However, there was considerable heterogeneity with a decline in DI associated with impaired SiBaseline after adjusting for age and weight changes (R2 = 0.22, p = 1.2 x 10-3). Of note, fasting glucagon concentrations at the time of initial study ([Glucagon]Baseline) were also significantly and inversely related to DIPresent (R2 = 0.13, p = 8 x 10-3). Baseline nadir and integrated (Area Under Basal-AUB) glucagon concentrations did not predict (p > 0.05) changes in DI. Fasting [Glucagon]Baseline, adjusted for age and weight changes interacts with SiBaseline to predict the longitudinal decline in DI (DIBaseline-DIPresent: (R2 = 0.29, p < 1 x 10-4). Taken together, these data suggest that defects in α-cell function, manifest as elevated fasting glucagon, drive subsequent decline in β-cell function. It remains to be ascertained if defects in postprandial-glucagon suppression attributable to or independent of, diabetes-associated genetic variation in TCF7L2 also interact with defects in fasting glucagon secretion to drive decline in β-cell function in nondiabetic humans.


J. Adams: None. M.C. Laurenti: Other Relationship; Self; GlySens Incorporated. M.D. Hurtado: None. C. Dalla Man: None. C. Cobelli: Research Support; Self; Sanofi-Aventis. Advisory Panel; Self; Novo Nordisk Inc.. R.A. Rizza: None. A. Vella: Research Support; Self; Novo Nordisk Inc., XOMA Corporation. Advisory Panel; Self; VTV Therapeutics, Bayer AG.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at